MedTrace Logo

Protective Effect of N-acetylcysteine Against From Ototoxicity

NCT01271088 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-11-16

No results posted yet for this study

Summary

Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by N-acetylcysteine

Conditions

  • Hearing Loss, Extreme

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics

Sponsors & Collaborators

  • TC Erciyes University

    lead OTHER

Principal Investigators

  • Ismail Kocyigit, MD · TC Erciyes University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01271088 on ClinicalTrials.gov